Economic TimesNovartis says Signifor LAR drug helps control acromegaly diseaseReuters IndiaZURICH (Reuters) – Swiss drugmaker Novartis said on Monday a final-stage trial of its Signifor LAR therapy allowed for greater disease control in patients with the endocrine disorder acromegaly than existing therapies. Acromegaly is caused by a benign …Novartis Presents Results From Signifor LAR Phase III Trial – Quick FactsNASDAQall 6 news articles …Read Full Story
Novartis says Signifor LAR drug helps control acromegaly disease - Reuters India
Real Estate of Cebu
